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NOVEL CHARACTERISTICS OF MLRINE BONE MARROW-DERIVED 
MACROPHAGES AND HUMAN MACROPHAGE-LIKE CELLS 
George T. Georges, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Jennifer K Stewart, Ph.D., Associate Professor, Department of Biology 
These studies provide evidence for novel properties of macrophages derived from 
bone marrow stem cells. In study 1, treatment of activated mouse bone marrow-derived 
macrophages (BMM) with either catecholamine synthesis inhibitors (a-methyl-para- 
tyrosine and fusaric acid) or the p2 adrenergic receptor antagonist ICI 1 18,55 1 
demonstrated that BMM produce catecl~olamines. The catecholamines modulated 
macrophage cytolune production through autocrine actions on adrenergic receptors. In 
study 11, undifferentiated human bone marrow cells were incubated in 30% mouse L929 
fibroblast conditioned medium and generated adherent cells within three days. The cells 
were clearly identifiable as macrophages based on surface proteins and phagocytic 
activity but produced only low levels of the cytokines tumor necrosis factor-a and 
interleulun-lp. Cytolune production did not increase in response to the bacterial 
vii 
endotoxin lipopolysaccharide (LPS). Generation of these macrophage-like cells was not 
repeatable with other samples of human bone marrow, but the cells continue to proliferate 
in cell culture and will be investigated further in future studies. 
Study 1 
Synthesis and Autocrine Actions of Catecholamines in Mouse 
Bone Marrow-Derived Macrophages 
Introduction 
Macrophages are a critical part of the innate immune response of host defense. 
Upon entering the body, bacteria and other foreign antigens are identified by the cells of 
the immune system, which act quickly to eliminate them. Macrophages are characterized 
by their ability to become activated in the presence of the foreign antigen. Activation 
stimulates macrophages to engulf particles by phagocytosis and to produce cytolunes that 
are important immune regulators. 
Macrophages are derived from the pluripotent hematopoeitic bone marrow stem 
cells. The process of differentiation requires chemical signals that allow the cells to 
develop along a specific cell lineage. In the case of macrophages, macrophage-colony 
stimulating factor (M-CSF) and granulocyte macrophage-colony stimulating factor (GM- 
CSF) are required to commit the cells to the myeloid cell lineage (17). The stem cells first 
develop into monocytes in the blood, whereby further development through continued 
stimulation results in the formation of localized, tissue-specific macrophages. 
Macrophages are known to express a2 and pz adrenergic receptors that enable the 
catecholamines, norepinephrine and epinephrine, to modulate cytolune production and 
influence immune function. Previous studies have demonstrated that binding of 
catecholamines or other adrenergic agonists to pz adrenergic receptors inhibits 
macrophage production of tumor necrosis factor-a (TNF- a)  and interleulun-1P (IL-1P) 
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(3; 11; 12; 16; 21; 22). Binding to a2 adrenergic receptors stimulates production of these 
cytokines (5; 6; 22; 23). 
Although catecholamines are produced primarily by neurons and the adrenal 
medulla, macrophages have been reported to take up catecholamines from extracellar 
fluids (1; 13), and catecholamines have been measured in peritoneal macrophages by two 
laboratories (15; 22). Scott Brown in our laboratory detected tyrosine hydroxylase (TH) 
mRNA, the rate limiting enzyme of the catecholamine synthesis pathway, in the 
RAW264.7 macrophage cell line following treatment with the bacterial endotoxin, 
lipopolysaccharide (LPS) (2). TH mRNA increased three fold from 24 h to 48 h after LPS 
treatment. In the same study, both intracellular and extracellular norepinephrine levels 
decreased in the presence of a-methyl-para-tyrosine (a-mpt), which prevents the activity 
of TH. These findings suggest that catecholamines are synthesized in RAW264.7 
macrophages. 
It is unclear whether catecholamines in primary macrophages are synthesized by 
these cells or taken up and stored for subsequent release. Several studies suggest that 
macrophages release norepinephrine. For example, our laboratory demonstrated that the 
RAW264.7 macrophage cell line releases norepinephrine (2), and Miller and colleagues 
found that human synovial macrophages release norepinephrine (19). Spengler and 
colleagues reported that intracellular levels of norepinephrine in peritoneal macrophages 
are reduced 30 minutes after the cells are stimulated with LPS (22), suggesting that 
intracellular catecholamines are released from macrophages into the extracellular 
environment upon stimulation. Additionally, there is evidence that macrophage 
production of cytokines is modulated by autocrine actions of macrophage-derived 
catecholamines binding adrenergic receptors. For example, treatment of peritoneal 
macrophages with adrenergic receptor antagonists (in the absence of exogenous 
catecholamines) modulates LPS stimulated production of the cytolunes tumor necrosis 
factor-alpha (TNF-a) (22) and interleukn- 1 p (IL- 1 P) (7). 
Although it is now clear that mouse peritoneal macrophages release 
catecholamines that exert autocrine effects on cytokne production, it is not known if this 
regulatory mechanism is present in newly differentiated murine bone marrow-derived 
macrophages. This question is important because bone marrow stem cells from 
experimental animals and human subjects are important precursors of macrophages, and 
these cells are often the major source of macrophages used for research. The focus of this 
study is to investigate whether mouse BMM synthesize catecholamines and whether 
catecholamines released by these cells display the same autocrine regulation of cytoknes 
through the adrenergic receptors as is seen in mouse peritoneal macrophages. 
Methods and Materials 
Cells 
Female CBAIJ mice (6-8 weeks of age) were obtained from Harlan (Indianapolis, 
IN), and 6 month old female C57BL6Jl129 mice were obtained from Tachonic 
(Germantown, NY). Mice were euthanized with COz. Cells were collected from tibia and 
femurs (4) and washed with complete RPMI (cRPMI) medium consisting of RPMI 1640 
(Invitrogen) supplemented with 10% heat inactivated-FBS, 1% L-glutamine, 1% non- 
essential amino acids, 1% minimal essential medium vitamins, 100 unitslml penicillin 
and 100 pglml streptomycin. The cells were seeded in tissue culture plates in fresh 
cRPMI with 30% L929-cell conditioned medium (a source of macrophage colony 
stimulating factor) (8; 18). Cells were incubated at 37 "C in a humidified 5% C 0 2  
atmosphere. After 24 hours, non-adherent cells were transferred to new 6 well tissue 
culture-treated plates to eliminate any early adherent cells such as fibroblasts. After 1 
week numerous adherent cells were evident, and the medium was replaced with fresh 
30% L-cell/70% cRPMI. The adherent cells were identified with a macrophage surface 
antigen and used in experiments the same week. 
Two cell lines, L929 mouse fibroblasts, and RAW264.7 macrophages were 
obtained from American Type Cell Culture (Manassas, VA). The cells were maintained 
in cRPMI in 75 cm2 tissue culture flasks. Stock cultures of L929 cells were sub-cultured 
weekly, and RAW264.7 cells were sub-cultured twice weekly. For collection of L929 
conditioned medium, approximately 200,000 L929 cells were seeded in 75 cm2 flasks in 
25 ml of cRPMI. Medium was removed after one week, and fresh cRPMI was added. The 
cells were maintained for a second week; then medium was again harvested, and cells 
were discarded. The media samples were centrifuged at 500 x g and 4 "C for 10 minutes, 
and filtered with either 0.22 pm PVDF-syringe filters (Fisher Scientific) or Steriflip 
vacuums filters with 0.22 pm PVDF membranes (Millipore Corporation, Billerica, MA), 
and stored frozen at -20 "C in polypropylene tubes. 
Bone marrow-derived mast cells were obtained from Mohit Kashyap in the 
laboratory of Dr. John Ryan, Virginia Commonwealth University. Mast cells were 
differentiated and maintained as previously described (9). 
Identification of Macrophages with F4/80 
F4180 is a surface antigen expressed by mature macrophages. Compared with 
other commonly used markers that are found on both fibroblasts and macrophages, F4/80 
is more specific for macrophages (14). For F4180 detection, cells were washed with fresh 
cRPMI medium and adjusted to 0.5x106cells/ml. An aliquot (180 p1) of the cells was 
added to a 96 well v-bottom plate, washed with phosphate buffered saline (PBS), and 
incubated with 10 pl of ascites 2.462 for 10 min to prevent non-specific binding to Fc-I1 
and Fc-I11 receptors. Samples were incubated with phycoerythrine (PE)-labeled anti- 
mouse F4180 antibody (eBioscience, San Diego, CA) at 2 pglml final concentration, 
while control samples were incubated with PE Rat IgG2a isotype control (eBioscience, 
San Diego, CA) at 20 pllwell. Following a 30 minute incubation, the wells were washed, 
and cells binding the labeled antibody were detected with a BD FACS Calibur flow 
cytometer. Results were analyzed with the BD CellQuest Pro software. Mouse mast cells 
and RAW264.7 macrophages were assayed as negative and positive controls, 
respectively. 
Effects of catecholamine synthesis inhibitors on LPS-stimulated IL-6 production 
Adherent cells in a 6 well plate were rinsed and removed with 3 ml of 0.25% 
(w/v) Trypsin + 0.53 mM EDTA. Fresh cRPMI was added to the cells, and 1 . 5 ~ 1 0 ~  cells 
per well were plated in a 24 well tissue culture-treated plate. The cells were incubated for 
4 h at 37°C in 5% C 0 2  to allow for adherence. BMM were then washed twice with warm 
(37°C) phosphate buffered saline, pH 7.4, and treated with 30 nglml LPS (E. coli - 
serotype 055:B5, Sigma) and catecholamine synthesis inhibitors (either 2 mM a-mpt or 
500 pM fusaric acid) in a final volume of 0.5 ml serum-free RPMI. a-mpt inhibits the 
activity of tyrosine hydroxylase, which converts L-tyrosine to L-dopa, and fusaric acid 
inhibits the activity of dopamine-P-hydroxylase, which converts dopamine to 
norepinephrine (20) (Figure 1). The macrophage monolayer in each well was washed 
with PBS, lysed in 150 p1 of lysis buffer (0.05 M Tris (pH 7.5), 0.3 M NaC1, 2 rnM 
EDTA, 0.5% Triton X-100, 2.0 pdml  leupeptin, 1 pglml aprotinin and 0.2 mM 
phenylmethylsulfonylflouoride), and then frozen at -20°C for future determination of 
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total cellular protein with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, 
CA) and read at 595 nm in the microplate spectrophotometer. 
Effects of the p2 adrenergic antagonists on LPS stimulated IL-IP production 
Bone marrow cells were treated with 30 nglml LPS (E. coli -serotype 055:B5, 
Sigma, St. Louis, MO) and 10 pM ICI 118,551 (p2 antagonist, Tocris, Ellisville, MO) in a 
final volume of 0.5 ml serum-free RPMI. Following a 24 h incubation, extracellular fluid 
was removed, centrifuged at 500 x g for 10 min at 4OC and then frozen at -30°C for future 
IL-1P assay. The macrophage monolayer in the wells was washed with PBS, lysed in 150 
yl lysis buffer as described above, and then frozen at -20 OC for future determination of 
total cellular protein with the Bio-Rad protein assay. 
Measurement of IL-6 and IL-IP 
Extracellular cytokine concentrations were assayed with an OptEIA Multi 
Component Elisa Set for Mouse IL-6 and a set for IL-113 (BD Biosciences, San Diego, 
CA) in accordance with the nlanufacturer's instructions. The plate was read at 450 and 
570 nm with a pQuant Universal Microplate Spectrophotometer (Bio-Tek Instruments, 
Winooski, VT). Concentrations were calculated with the manufacturer's KC4 software. 
Statistical analysis of all data was performed with GraphPad Prism, version 4.02. 
Results 
Verification of macrophage phenotype 
Approximately 50% of the bone marrow-derived cells began to show adherence 
on day two of incubation following marrow extraction. By day 4, nearly 80% of the cells 
in each flask were healthy differentiated adherent cells with defined pseudopodia. The 
cells displayed a high fluorescence intensity for the mature macrophage marker F4180, 
and the expression of F4180 in the BMM was similar to that of the positive control (RAW 
264.7 macrophage cells) (Figure 2). 
EfSects of catecholamine synthesis inhibitors on IL-6 release 
Catecholamine synthesis inhibitors significantly reduced extracellular levels of 
IL-6. When treated with LPS + the tyrosine hydroxylase inhibitor a-mpt, extracellular IL- 
6 decreased three fold when compared with LPS treatment alone (Figure 3). When the 
BMM were treated with LPS + fusaric acid, an inhibitor of dopamine-P-hydroxylase, 
similar results were observed (Figure 4). These findings suggests that mouse BMM 
synthesize catecholamines that exert autocrine effects on the release of IL-6. 
Furthermore, because fusaric acid inhibits synthesis of norepinephrine and epinephrine, 
but not doparnine (Figure 2), the results suggest that IL-6 release is stimulated by BMM- 
derived norepinephrine or epinephrine. 
Autocrine actions of macrophage-derived catecholamines on IL-lp release 
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When the BMM were treated with 30 nglml LPS and the P2-adrenergic receptor 
antagonist ICI, the extracellular IL-1P levels increased two fold over those observed with 
LPS alone (Figure 5 )  suggesting that P2 adrenergic agonists released by BMM inhibit 
LPS-stimulated production of IL-1 P. These results parallel those previously observed 
with peritoneal macrophages (7) and suggest that BMM-derived catecholarnines display 
an autocrine effect on IL- 1 P mediated through the P2-adrenergic receptor. 
Discussion 
This study is the first to demonstrate that newly differentiated bone marrow- 
derived macrophages (BMM) produce catecholamines, which modulate extracellular 
levels of IL-1P and IL-6 produced by the macrophages. The autocrine actions of 
catecholamines on the P2-adrenergic receptor in BMM are consistent with the results of 
previous studies on peritoneal macrophages (7). Further investigation is needed to 
determine whether BMM express the w2-adrenergic receptor and to determine the 
receptor mediating autocrine effects of BMM-derived catecholamines on release of IL-6. 
These findings are important for our understanding of regulatory mechanisms in BMM 
and because BMM are frequently used to study macrophage functions. 
.methyl-para-tyrosine Tyrosine hydroxylase (TH) 
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decarboxylase 
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methyltransferase (PNMT) 
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Figure 1. Catecholamine synthesis pathway. a-methyl-para-tryosine inhibits the actions 
of tyrosine hydroxylase (TH), preventing the synthesis of L-DOPA, dopamine, 
norepinephrine, and epinephrine. Fusaric acid inhibits the actions of Dopamine P- 
hydroxylase (DBH), preventing the synthesis of norepinephrine and epinephrine only. 
Fluorescence Intensity - 
Figure 1: Expression of F4180 in mouse BMM. The shaded regions indicate non-specific 
background staining, and lines represent triplicate samples with F4180 staining. (a) The 
RAW 264.7 macrophage cells were a positive control. (b) Mast cells, a negative control, 
showed no significant expression of F4180. (c) The F4180 staining of bone marrow- 
derived cells was comparable to that of the positive controls cells. 
Vehicle LPS LPS + a-mpt 
Vehicle LPS LPS + a-mpt 
Figure 3: Bone marrow derived macrophages were treated with LPS and the 
catecholamine synthesis inhibitor a-methyl-para-tyrosine (a-mpt). a) Extracellular IL-6 
was measured to determine the effects of catecholamine synthesis on mouse BMM 
cytokine release. b) Protein levels were not different among treatment groups. 
* P < 0.001 compared to LPS alone. 
Vehicle LPS 
-r 
LPS + Fus. Acid 
Vehicle LPS LPS + Fus. Acid 
Figure 4: Bone marrow derived macrophages were treated with LPS and the 
catecholamine synthesis inhibitor fusaric acid. (a) Extracellular IL-6 was measured to 
determine the effects of norepinephrine and epinephrine synthesis on mouse BMM 
cytolune release. (b) The concentration of protein in each treatment group did not differ 
significantly. * P < 0.001 compared to LPS alone. 
Vehicle LPS LPS + ICI 
Figure 5: Adrenergic receptor antagonists modulate LPS-stimulated release of IL-1P in 
BMM. Murine BMM were treated with LPS and 10 pM ICI 118,551 (ICI) (P2 adrenergic 
receptor antagonist) for 24 hrs. IL-1P was measured with a BD ELISA IOt. LPS 
significantly stimulated the production of IL-lP, while the addition of ICI further 
increased extracellular levels of IL-1P. * P < 0.01 compared to LPS alone. 
Study 2 
Differentiation and Characterization of Human Bone Marrow-Derived 
Macrophage-Like Cells 
Introduction 
Hematopoiesis is the critical process of bone marrow stem cell development. 
Undifferentiated cells derived from the bone marrow have the potential to become one of 
many mature specialized cell components of blood. The process of cell differentiation is 
mediated through a cell signaling mechanism involving the actions of specific cytolunes 
and growth factors. In the case of macrophages, hematopoietic stem cells respond to 
macrophage-colony stimulating factor (M-CSF) and granulocyte macrophage-colony 
stimulating factor (GM-CSF)(8; 17). M-CSF is a survival, growth, differentiation, and 
activating factor for macrophages and their progenitor cells. In the presence of these 
cytokines, the cells commit to the myeloid cell lineage. These premature cells known as 
monocytes are directed into the blood circulation where they continue their development 
into macrophages under the continued influence of these cytokines. Interleukin-6 (IL-6) 
is a cytokine produced by several types of cells including fibroblasts and is also important 
in macrophage development (10). 
L929 cells are a mouse fibroblast cell line known for continuous production of M- 
CSF and IL-6. Studies have shown that macrophages differentiate from mouse femur- 
derived stem cells when grown in L929 conditioned medium (4). These mouse bone- 
marrow derived macrophages have been the subject of several ongoing experiments 
within our laboratory, and we were interested in continuing this research with human 
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bone marrow-derived macrophages. Although investigators recently discovered a human 
cell line that produces factors needed for human macrophage differentiation (lo), this cell 
line is not available. Treating human stem cells with L929-conditioned medium did not 
seem feasible because mouse derived M-CSF and IL-6 are documented as not displaying 
cross-reactivity with human cytokine receptors (8) Nevertheless, we could find no 
evidence that mouse L929 medium has ever been tested on human cells. It is known that 
native cytokine proteins found in conditioned medium may differ in biological activity 
from the recombinant proteins often used to test for cross reactivity (18). Also, 
conditioned medium may contain unidentified factors that affect growth and 
differentiation. 
In this study, the effects of mouse L929 fibroblast conditioned medium on 
development of undifferentiated human bone marrow cells was investigated. 
Methods and Materials 
Cells 
Human bone marrow cells (cat. # ABMOOI-1) were obtained from Stem Cell 
Technologies (Berkeley, CA). Cells were washed with complete RPMI (cRPMI) medium 
consisting of RPMI 1640 (Invitrogen) supplemented with 10% heat inactivated-FBS, 1% L- 
glutarnine, 1% non-essential amino acids, 1% minimal essential medium vitamins, 100 unitsiml 
penicillin and 100 pgiml streptomycin. The cells were seeded into tissue culture plates in fresh 
cRPMI with 30% L929-cell conditioned medium (a source of macrophage colony stimulating 
factor)(4; 18). Cells were incubated at 37 T in a humidified 5% C 0 2  atmosphere for 1 week. 
Adherent cells were visible within 4 days. 
Mouse L929 fibroblasts and RAW264.7 macrophages were maintained as described in 
Study 1. Human dermal fibroblasts were obtained through Dr. Dome Yager from the Plastic 
Surgery Department, Medical College of Virginia at Virginia Commonwealth University. These 
cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, cat. # 30-2002) from 
ATCC (Manassas, VA) supplemented with 10% heat inactivated-FBS and 100 pg/ml 
streptomycin. HEPG2 cells were obtained through Dr. Qibing Zhou, Department of Chemistry at 
Virginia Commonwealth University, and were maintained by Lin Zhang. All cells were 
incubated at 37°C in a humidified 5% C 0 2  atmosphere. 
2 1 
Identification of Surface Markers with Flow Cytometry 
Fibroblasts are a major contaminant in adherent cell cultures. They adhere to the surface 
of flasks and resemble macrophages in shape and size. To address this concern, the adherent 
bone marrow-derived cells were assayed with flow cytometry to detect cell specific surface 
antigens for both macrophages and fibroblasts. Cells were washed and adjusted to 1 x 1 0 ~  cells/ml 
cRPMI. In a v-bottom tissue culture-treated plate, 180 p1 of bone marrow cells were added to 
each well, washed, and blocked with 10 p1 of 2.462 rat ascites for 10 minutes at 4OC. Samples 
included positive and negative control cells. Cells were incubated with antibodies to surface 
markers for 30 minute at 4 OC, then analyzed by flow cytometry (BD, Facs Calibur) with BD 
CellQuest Pro software. Macrophage cell surface markers included Mac-1 (identified with 2 
pglml (phycoerythrin) PE-anti-Mac-1, egiosciences) and F4/80 (identified with 2 pglml PE-anti- 
F4/80, eBiosciences). The fibroblast marker AS02 (identified with 2 pglrnl l o  mouse anti-human 
AS02 and 10 pglml 2" PE-goat anti-mouse AS02, eBiosciences) was used to identify any 
contaminating fibroblasts. For macrophage identification with Mac-1, cells were compared with 
the mouse macrophage cell line RAW264.7, which were the positive control cells, and with the 
mouse fibroblast L929 cell line that was used as a negative control. For macrophage 
identification with F4180, RAW264.7 cells were positive controls, and human dermal fibroblasts 
were negative control cells. For fibroblast identification, human dermal fibroblasts and HEPG2 
hepatocytes were used as positive and negative controls respectively. 
Phagocytosis Assay 
Phagocytosis of bacteria was measured with the Vybrant Phagocytosis IQt (Invitrogen V- 
6694). All cells, including adherent human bone marrow-derived cells, positive controls 
(RAW264.7) and negative controls (human dermal fibroblasts) were adjusted to 1 x 1 0 ~  cells/ml in 
cRPMI medium, and 150 pllwell were added to a 96 well plate. Cells were incubated for 1 h to 
allow for adherence. Following incubation, the medium was replaced with E. coli fluorescein 
(F1TC)-labeled BioParticle suspension, and the cells were then incubated for 2 h. The cells were 
then washed, and any remaining extracellular fluorescence was immediately quenched with 
trypan blue. Samples were read in a Wallac victor2 rnultilabel counter (Perkln Elmer) at settings 
of 480 nm excitation and 520 nm emission. 
Cells were also incubated separately with the FITC-labeled BioParticle suspension on 
microscope slides for 2 h and mounted with Vectasheild mounting media. The cells were viewed 
with an Opelco IX-70 fluorescent inverted phase contrast microscope (OPELCO, Dullas, VA). 
Images were saved with the QCapture software (OPELCO) and adjusted for size with Arcsoft 
Photoimpression software. 
EfSects ($LPS and adrenergic antagonists on TNF-a & IL-lp 
Bone marrow derived cells were scraped gently from tissue culture-treated flasks 
(Corning brand, Fisher Scientific)(4), and for each treatment, 1 . 5 ~ 1 0 ~  cells were added to each 
well in a 24 well tissue culture-treated plate (Costar brand, Fisher Scientific) in 0.5 ml serum- 
free cRPMI. The cells were incubated for 4 h at 37 OC in 5% COz to allow cell adherence. The 
cells were then washed twice with warm (37 "C) phosphate buffered saline, pH 7.4, treated with 
30 nglml LPS (E. coli -serotype 055:B5, Sigma) and either 10 pM ICI (P2 antagonist, ICI- 
118,55 1, Tocris) or 5 pM Yohimbine (a2 antagonist, Sigma), all in a final volume of 0.5 ml 
serum-free RPMI. Following a 24 h incubation, extracellular fluid was removed, centrifuged at 
500 x g for 10 min at 4 OC and then frozen at -20 OC for future IL-1PI TNF-a assays. The cell 
monolayers in the wells were washed with PBS, lysed in 150 p1 lysis buffer (0.05 M Tris (pH 
7.5), 0.3 M NaC1, 2 mM EDTA, 0.5% Triton X, 2.0 pglml leupeptin, 1 pglml aprotinin and 0.2 
2 3 
mM phenylmethylsulfonylflouoride), and then frozen at -20 "C for future determination of 
total cellular protein. 
Measurement of ZL-lp, TNF-a, and total cellular protein 
Extracellular concentrations of IL-1P were assayed with the OptEIA Multi Component 
Elisa Set for Mouse IL-1P (BD Biosciences, San Diego, CA). The assay was performed in 
accordance with the manufacturer's instructions. The plate was read at 450 and 570 nm with a 
pQuant Universal Microplate Spectropl~otometer (Bio-Tek Instruments, Winooski, VT), and 
concentrations were calculated with the manufacturer's KC4 software. Cell lysates were assayed 
for total protein with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) and read 
at 595 nm in the microplate reader. 
Results 
Identification of Cells 
Identifying surface antigens that are specific for macrophages was an important initial 
step in characterizing the human bone marrow-derived cells. The first of these surface markers 
identified was MAC-1. When analyzed with flow cytometry, the MAC-1 surface antigen was 
identified on all of the cells, including the negative control cells (L929 fibroblasts), indicating 
that it was not a specific indicator of macrophages (Figure 1). The F4180 surface antigen showed 
a higher degree of specificity for macrophages (Figure 2) (14). Compared with the positive and 
negative controls, human bone marrow-derived cells exhibited a high fluorescence intensity for 
F4180, indicating that these cells were similar to mature macrophages. When the cells were 
examined for AS02, a fibroblast specific surface marker, the bone marrow-derived cells 
exhibited low fluorescence intensity equaling the nonspecific fluorescence (Figure 3). Human 
dermal fibroblasts (positive control) exhibited a high fluorescence intensity for AS02 as 
expected. This result suggests that the bone marrow-derived cells are not fibroblasts. 
Phagocytosis 
The phagocytosis assay revealed that the human bone marrow-derived cells are 
phagocytic (Figure 4). They cells engulfed the bacteria with a little over half the efficiency of the 
RAW macrophage cell line (positive control). Human dermal fibroblasts did not show any 
phagocytic activity. This finding indicates that the cells not only express macrophage specific 
surface antigens but also are phagocytic. 
RAW macrophages that were incubated on slides with the fluorescent bioparticle 
suspension (FITC-Bacteria) were viewed with fluorescence microscopy (Figure 5). Cells not 
receiving the suspension were examined for background fluorescence. The RAW macrophages 
did not show any significant background fluorescence, and phagocytosis of particles was evident 
in cells treated with the FITC-Bacteria. Human bone marrow derived cells exhibited phagocytic 
activity comparable to that exhibited with the RAW macrophage cell line and exhibited no 
background fluorescence in the absence of the fluorescent bioparticle incubation (Figure 6). A 
bright-field view of the slide without the fluorescent incubation confirmed the presence of the 
cells when no fluorescence was evident. 
Cytokine Production 
The human bone marrow-derived cells did not produce cytolunes in a manner typical of 
macrophages. Low concentrations of TNF-a were produced continuously but did not increase in 
response to LPS stimulation. The constitutive release of TNF-a did not appear to be altered by 
LPS in either a time or dose dependent pattern (Figure 7). Furthermore, the cells produced only 
low concentrations of IL-1P (Figure 8). LPS and adrenergic antagonists known to modulate IL- 
l p  release (7; 22) also had no significant effect on extracellular levels of this cytolune. 
Discussion 
The human bone marrow-derived cells investigated in this study can be described as 
macrophage-like cells, as they have been found to express macrophage specific surface antigens 
and exhibit phagocytic activity. The cells do not, however, produce cytolunes in response to LPS 
as would be expected of macrophages. This new cell line proliferates in culture in cRPMI 
(without L929-conditioned medium) and reaches confluency within several days of seeding. 
Further studies are needed to investigate the mechanisms regulating cytokine production in this 
new cell line. 
Newly differentiated monocytes require specific signals for continued development to 
macrophages. It is unclear whether L929-conditioned medium provided the signals for the 
human bone marrow cells to differentiate into macrophage-like cells or whether the cells were 
transformed in vivo. Cytolunes such as M-CSF and L - 6  have been identified for their key roles 
in macrophage differentiation. For example, IL-6 is reported to up-regulate M-CSF receptors on 
the surface of macrophages (10). L929 fibroblasts produce mouse IL-6 and M-CSF, but it is 
unclear whether these mouse cytolunes bound to receptors on the human cells. Also, it is 
possible that other unidentified growth factors needed for normal mouse bone marrow cell 
differentiation and development may not have cross reacted with receptors on human cells. 
Because we were not able to repeat this study with human bone marrow cells incubated in L929- 
conditioned medium, it is conceivable that the cells in this study were transformed to a 
continuously proliferating cell line in vivo. The cells are easily maintained in culture and will be 
used for future studies of macrophage-like functions. 
Fluorescence Intensity - 
Figure 1: MAC-1 staining for macrophages. Shaded areas indicate background non-specific 
staining. Lines represent duplicate samples. (a) RAW 264.7 macrophages stained for MAC-1 
(positive control). (b) Mouse L929 fibroblasts, a negative control, also showed high fluorescence 
for MAC-1 indicating that MAC-1 is not a macrophage-specific marker. (c) Human bone 
marrow-derived cells also stained for MAC-1. 
Fluorescence Intensity , 
Figure 2: F4180 (mature macrophage marker) staining. Shaded areas indicate background non- 
specific staining. Lines represent triplicate samples. (a) The RAW 264.7 macrophage cell line 
was stained as a positive control for this marker. (b) Human dermal fibroblasts showed no 
specific staining. (c) Human bone marrow-derived cells were positive for F4180. 
Fluorescence Intensity - 
Figure 3: AS02 (fibroblast-specific surface marker) staining. Shaded areas indicate background 
non-specific staining. Lines represent triplicate samples. (a) Human dermal fibroblasts, positive 
control cells, stained for AS02. (b) A hepatocyte carcinoma cell line HEP-G2, negative control 
cells, showed no staining for the fibroblast-specific protein. (c) The human bone marrow-derived 
cells showed no staining for AS02. 
P hagocytosis Assay 
Figure 4: Phagocytic activity of human bone marrow-derived cells and control cells. Phagocytic 
cells (RAW), non-phagocytic (human dermal fibroblasts) (FTBRO), and human bone-derived 
cells were assayed in the absence of bacteria to account for background fluorescence or 
incubated with fluorescein-labeled bacteria (FITC-BACT). 
RAW macrophages Raw macrophages wlout 
treated w l  FITC-Bact. - FITC-Bact. treatment 
Figure 5: RAW 264.7 macrophages incubated with the fluorescent bioparticle suspension. (a) 
High fluorescence of intracellular bacteria was observed with an inverted phase contrast 
microscope. (b) Cells that were not incubated with fluorescent bacteria showed minimal to no 
fluorescence, indicating that endogenous macrophage fluorescence is negligible. 
Magnification = 400X 
HUMAN CELLS 
Top Left: Human Cells Treated w l  FITC-Bact. 
Top Right: Human Cells wlout FITC-Bact. 
Bottom: Bright field view of human cells wlout 
FICT-Bact. 
Figure 6:  Cells treated with the fluorescent bacteria revealed a high level of phagocytosis 
activity (top left). Cells that were incubated without the bacteria showed only minimal 
background fluorescence as expected (top right). A bright field view (bottom right) of the cells 
(top right) confirmed the presence of the bone marrow-derived cells on the slide. 
Magnification = 400X 
Figure 7: TNF-a production by the human macrophage-like cells following a 2,4, and 6 hour 
incubation with 30 ng/ml LPS. Additionally, cells were treated for a 2 h incubation with 100 
ng/ml LPS. 
Figure 8: ILl-P production by the human macrophage-like cells assayed following a 24 h 
incubation with LPS, LPS+ICI-118,551 (ICI), or LPS+Yohimbine (YOH). These bone marrow- 
derived cells did not respond to LPS stimulation and produced little IL-1P. 
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